Revolution Medicines, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
RVMD$193.06-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(a)
The following documents are filed as part of this Annual Report on Form 10-K:
Financial Statements:
The following financial statements and schedules of the Registrant are contained in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K:
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm | 90 |
| Consolidated Balance Sheets | 92 |
| Consolidated Statements of Operations and Comprehensive Loss | 93 |
| Consolidated Statements of Stockholders’ Equity | 94 |
| Consolidated Statements of Cash Flows | 95 |
| Notes to Consolidated Financial Statements | 96 |
Financial Statement Schedules
No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes thereto.
(b)
Exhibits
The exhibits listed in the following “Exhibit Index” are filed, furnished or incorporated by reference as part of this Annual Report.
Exhibit Index
| Incorporated by reference · Filedherewith | |||||
|---|---|---|---|---|---|
| Exhibitnumber · Exhibit description · Form · Date · Number | |||||
| 1.1 · Sales Agreement, dated as of February 25, 2026, by and between Revolution Medicines, Inc. and TD Securities (USA) LLC. · X | |||||
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 2/18/2020 | 3.1 | |
| 3.2 | Amended and Restated Bylaws. | 8-K | 3/8/2021 | 3.1 | |
| 4.1 | Reference is made to Exhibits 3.1 through 3.2. | ||||
| 4.2 | Form of Common Stock Certificate. | S-1 | 1/17/2020 | 4.2 | |
| 4.3 | Description of Securities. | X | |||
| 4.4A | Warrant Agreement, dated April 6, 2021, by and between Continental Stock Transfer & Trust Company and EQRx, Inc. | 10-K | 2/26/2024 | 4.4(a) | |
| 4.4B | Appointment, Assignment and Assumption Agreement, dated November 9, 2023, by and among EQRx, Inc., Revolution Medicines, Inc., Continental Stock Transfer & Trust Company and Equiniti Trust Company, LLC. | 8-A | 11/15/2023 | 4.2(b) | |
| 5.1 | Opinion of Latham & Watkins LLP | X | |||
| 10.1A† | Collaborative Research, Development and Commercialization Agreement, dated as of June 8, 2018, by and between Revolution Medicines, Inc. and Aventis, Inc., as amended. | S-1 | 1/17/2020 | 10.1 | |
| 10.1B† | Letter Agreement and Amendment, dated as of August 5, 2021 by and between Revolution Medicines, Inc. and Genzyme Corporation. | 10-Q | 8/11/2021 | 10.2 | |
| 10.2A | Lease between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of January 15, 2015. | S-1 | 1/17/2020 | 10.3A | |
| 10.2B | First Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of September 16, 2016. | S-1 | 1/17/2020 | 10.3B | |
| 10.2C | Sublease between OncoMed Pharmaceuticals, Inc. and Revolution Medicines, Inc., dated as of January 16, 2019. | S-1 | 1/17/2020 | 10.3C | |
| 10.2D | Second Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of April 17, 2020. | 10-Q | 5/14/2020 | 10.4 | |
| 10.2E | Third Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of November 1, 2021. | 10-Q | 11/10/2021 | 10.1 | |
| 10.2F | Fourth Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of March 24, 2023 | 10-Q | 5/8/2023 | 10.2 | |
| 10.2G | Fifth Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of August 3, 2023 | 10-Q | 11/6/2023 | 10.3 | |
| 10.2H | Sixth Amendment, dated as of July 12, 2024, to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc. | 10-Q | 11/6/2024 | 10.1 | |
| 10.2I | Seventh Amendment, dated as of November 5, 2024, to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc. | 10-K | 2/26/2025 | 10.2I | |
| 10.2J | Eighth Amendment, dated as of July 28, 2025, to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc. | 10-Q | 11/5/2025 | 10.1 | |
| 10.2K | Sublease between Editco Bio Inc. and Revolution Medicines, Inc., dated as of November 5, 2024 | 10-K | 2/26/2025 | 10.2J | |
| Incorporated by reference · Filedherewith | |||||
|---|---|---|---|---|---|
| Exhibitnumber · Exhibit description · Form · Date · Number | |||||
| 10.3†^ | Revenue Participation Right Purchase and Sale Agreement dated June 23, 2025, by and between Royalty Pharma Investments 2019 ICAV and the Company. | 10-Q | 8/6/2025 | 10.1 | |
| 10.4†^ | Loan Agreement dated June 23, 2025, by and among Wilmington Trust, National Association, as trustee, Royalty Pharma Development Funding, LLC, and the Company. | 10-Q | 8/6/2025 | 10.2 | |
| 10.5A# | 2014 Equity Incentive Plan, as amended. | S-1 | 1/17/2020 | 10.6(a) | |
| 10.5B# | Form of Amended and Restated Early Exercise Stock Option Grant Notice and Amended and Restated Stock Option Agreement under 2014 Equity Incentive Plan, as amended. | S-1 | 1/17/2020 | 10.6(b) | |
| 10.6A# | 2020 Incentive Award Plan. | S-1/A | 2/3/2020 | 10.7(a) | |
| 10.6B# | Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan. | S-1/A | 2/3/2020 | 10.7(b) | |
| 10.6C# | Form of Restricted Stock Award Agreement under the 2020 Incentive Award Plan. | S-1/A | 2/3/2020 | 10.7(c) | |
| 10.6D# | Form of Restricted Stock Unit Award Grant Notice under the 2020 Incentive Award Plan. | S-1/A | 2/3/2020 | 10.7(d) | |
| 10.7# | 2020 Employee Stock Purchase Plan. | S-1/A | 2/3/2020 | 10.8 | |
| 10.8A# | Employment Agreement by and between Revolution Medicines, Inc. and Mark A. Goldsmith, M.D., Ph.D. | S-1 | 1/17/2020 | 10.9 | |
| 10.8B# | First Amendment to Employment Agreement dated June 10, 2022 by and between Revolution Medicines, Inc. and Mark Goldsmith, M.D., Ph.D. | 8-K | 06/10/2022 | 10.1 | |
| 10.8C# | Second Amendment to Employment Agreement dated January 1, 2026 by and between Revolution Medicines, Inc. and Mark Goldsmith, M.D., Ph.D. | X | |||
| 10.9A# | Employment Agreement by and between Revolution Medicines, Inc. and Steve Kelsey, M.D., FRCP, FRCPath. | S-1 | 1/17/2020 | 10.10 | |
| 10.9B# | First Amendment to Employment Agreement dated January 1, 2026 by and between Revolution Medicines, Inc. and Steve Kelsey, M.D., FRCP, FRCPath. | X | |||
| 10.10A# | Employment Agreement by and between Revolution Medicines, Inc. and Margaret Horn, J.D. | S-1 | 1/17/2020 | 10.11 | |
| 10.10B# | First Amendment to Employment Agreement dated January 1, 2026 by and between Revolution Medicines, Inc. and Margaret Horn, J.D. | X | |||
| 10.11A# | Employment Agreement, dated as of August 1, 2024 by and between Revolution Medicines, Inc. and Jack Anders. | 10-Q | 08/07/2024 | 10.2 | |
| 10.11B# | First Amendment to Employment Agreement, dated January 1, 2026 by and between Revolution Medicines, Inc. and Jack Anders. | X | |||
| 10.12A# | Employment Agreement dated as of August 1, 2024 by and between Revolution Medicines, Inc. and Xiaolin Wang, Sc.D. | 10-Q | 08/07/2024 | 10.3 | |
| 10.12B# | First Amendment to Employment Agreement dated January 1, 2026 by and between Revolution Medicines, Inc. and Xiaolin Wang, Sc.D. | X | |||
| 10.13# | Non-Employee Director Compensation Program. | 10-Q | 05/07/2025 | 10.1 | |
| Incorporated by reference · Filedherewith | |||||
|---|---|---|---|---|---|
| Exhibitnumber · Exhibit description · Form · Date · Number | |||||
| 10.14# | Form of Indemnification Agreement for directors and officers. | S-1/A | 2/3/2020 | 10.13 | |
| 19.1^ | Insider Trading Compliance Policy and Procedures | 10-K | 2/26/2025 | 19.1 | |
| 21.1 | Subsidiaries of Registrant. | X | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm. | X | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 97 | Policy for Recovery of Erroneously Awarded Compensation | 10-K | 02/26/2024 | 97 | |
| 101.INS | Inline XBRL Instance Document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document. | X | |||
| 104 | The cover page from Revolution Medicines, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025, formatted in Inline XBRL and contained in Exhibit 101. | X | |||
† Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is the type of information that Revolution Medicines, Inc. treats as private or confidential.
^ Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. Revolution Medicines, Inc. undertakes to furnish a copy of all omitted schedules and exhibits to the Securities and Exchange Commission upon its request.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.